Global Adalimumab Monoclonal Antibody Biosimilar Market Growth 2023-2029

Global Adalimumab Monoclonal Antibody Biosimilar Market Growth 2023-2029

The global Adalimumab Monoclonal Antibody Biosimilar market size is projected to grow from US$ 411.8 million in 2022 to US$ 966.9 million in 2029; it is expected to grow at a CAGR of 13.0% from 2023 to 2029.

The introduction of Humira biosimilars is expected to increase competition in the market, leading to lower prices and improved access to treatment for patients. The availability of biosimilars provides an alternative option for healthcare providers and payers to choose from, potentially reducing the overall healthcare expenditure associated with biologic treatments.

Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.

LPI (LP Information)' newest research report, the “Adalimumab Monoclonal Antibody Biosimilar Industry Forecast” looks at past sales and reviews total world Adalimumab Monoclonal Antibody Biosimilar sales in 2022, providing a comprehensive analysis by region and market sector of projected Adalimumab Monoclonal Antibody Biosimilar sales for 2023 through 2029. With Adalimumab Monoclonal Antibody Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Adalimumab Monoclonal Antibody Biosimilar industry.

This Insight Report provides a comprehensive analysis of the global Adalimumab Monoclonal Antibody Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Adalimumab Monoclonal Antibody Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Adalimumab Monoclonal Antibody Biosimilar market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Adalimumab Monoclonal Antibody Biosimilar and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Adalimumab Monoclonal Antibody Biosimilar.

This report presents a comprehensive overview, market shares, and growth opportunities of Adalimumab Monoclonal Antibody Biosimilar market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Syringe
Pen

Segmentation by application
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Cadila Healthcare
Torrent Pharmaceuticals
Amgen
Boehringer Ingelheim
Novartis
Samsung Bioepis
Viatris
Pfizer
Fresenius Kabi
Coherus

Key Questions Addressed in this Report

What is the 10-year outlook for the global Adalimumab Monoclonal Antibody Biosimilar market?

What factors are driving Adalimumab Monoclonal Antibody Biosimilar market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Adalimumab Monoclonal Antibody Biosimilar market opportunities vary by end market size?

How does Adalimumab Monoclonal Antibody Biosimilar break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.